The long term findings of a study carried out at Hammersmith hospital reveal that testing for Human Papilloma Virus (HPV) can be twice as effective at protecting women from developing cervical abnormalities as smear testing. Results of the research – led by Professor Jack Cuzick of Barts and The London School of Medicine and Dentistry - are published today in the International Journal of Cancer.
Nearly 3,000 women aged 35+ were recruited into the study between April 1994 and September 1997. They were asked to participate in a study in which HPV testing would be performed in addition to cytology (smear test) whilst attending their GP practice (40 practices were involved in the trial) for a routine cervical smear.
Women who had previously been treated for cervical intra-epithelial neoplasia (CIN) – changes to cells in the cervix that can develop into cancer – or had experienced any cervical abnormality within the previous 3 years, were excluded from the study.
All women tested were followed up passively using data from the national computerised system that records all smears and their results – the Open-Exeter system. Women with a smear history indicating the need for colposcopy – a more thorough examination of the cervix – were investigated further to determine whether the colposcopy and biopsy were performed, and what the resultant outcome was. Passive follow-up was complete for all women by early 2005.
Results showed that the risk of developing cervical abnormalities at 1, 5, and 9 years after a normal smear test was 0.33 per cent, 0.83 per cent, and 2.20 per cent respectively, with those odds significantly reduced after a negative HPV test - 0.19 per cent, 0.42 per cent, and 1.88 per cent.
Professor Jack Cuzick said: “Not only does the research confirm that HPV testing detects more disease at each smear, it shows that this approach offers women excellent protection from cervical abnormalities for at least 6 years after a negative test, compared to protection from a normal smear test which begins to wane after about 3 years.
This suggests that the screening interval can be safely extended to at least 6 years with HPV testing. These data provide more support for replacing screening based on abnormal cells, with a more sensitive test based on screening for the human papillomavirus.”
Source: Queen Mary, University of London
Related stories:
Only 1 in 5 women in developing world receive effective cervical cancer screening
Few women in the developing world are screened effectively for cervical cancer and those at highest risk of developing the disease are among the least likely to be screened, accordingly an analysis published in
PLoS Medicine. The study, by Emmanuela Gakidou (University of Washington, Seattle, USA) and colleagues, also finds striking inequalities in access to cervical cancer screening between and within countries.
Obese women in Canada are less likely to be screened for cervical cancer
Research in the United States has shown that obese people are less likely than their normal-weight peers to undergo screening for breast, colon and cervical cancer. Raj Padwal, Rebecca Mitchell and Scott Klarenbach, from the University of Alberta's Faculty of Medicine & Dentistry, have undertaken a study to see if this trend is also true in Canada.
Study firms up promise of potential new cervical cancer screening tool
New research into the causes of cervical cancer appears to lend weight to the promise of a potential early detection method that could help prevent the disease.
HPV vaccine reduces abnormal pap test results
In testing GARDASIL reduced abnormal Pap test results by 43 percent compared to women not given the vaccine, according new research. The findings show the approved anti-HPV agent appears to prevent the development of cell changes that lead to cervical disease, said a researcher at the University of Alabama at Birmingham. The reduction in abnormal Pap results were presented at a conference Monday in Tampa.
Early detection of human papilloma and other viral infections
Scientists in Iowa are reporting development of a new, amazingly sensitive method for identifying the earliest stages of infection with human papilloma virus (HPV), a common virus that can increase the risk of cervical cancer in women. The test also has the potential for early identification of infection with other so-called DNA viruses, which cause a range of diseases that includes genital herpes and hepatitis. Their report is scheduled for the Nov. 1 issue of ACS’
Analytical Chemistry.
Cervical cancer screening: Too many are left unprotected
The decline in cervical cancer is a success story of cancer research. Although there are reasons to be optimistic about even further decreases in cervical cancer incidence, there still remain some women who are not screened. A meta-analysis by Spence and colleagues published in the August-September 2007 issue of
Preventive Medicine shows that undergoing Pap smears irregularly or never was the primary explanation for the development of invasive cervical cancer, followed by false negative tests and poor follow-up of abnormal results.
Analysis of cancer incidence, mortality and survival combined reveals encouraging European trends
The first research to look at recent trends in European cancer incidence, mortality and survival together has shown that cancer prevention and management in Europe is moving in the right direction. However, the research reveals that variations between countries in policies for mass screening, access to health care and treatment are reflected in the different cancer rates.
Cancer incidence and mortality in young people decreases with increasing deprivation
Results of research into the associations between cancer and socio-economic deprivation and affluence have shown that, in contrast to cancers in older people, the numbers of new cases and deaths from the disease in teenagers and young adults (TYAs) decrease with increasing deprivation.